Clinical Trials Browser

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT06523621 2026-03-04

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Phase 2 Recruiting

50 enrolled

Plasma cell

Multiple Myeloma

NCT02693535 2026-02-13

TAPUR

Phase 2 Recruiting

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT04205409 2025-11-03

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Phase 2 Active not recruiting

20 enrolled 12 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02719613 2025-06-05

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase 2 Active not recruiting

67 enrolled

Plasma cell

Multiple Myeloma

NCT06400264 2024-05-06

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Phase 2 Withdrawn

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT04119336 2023-08-21

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

Phase 2 Terminated

2 enrolled 6 charts

Plasma cell

Multiple Myeloma

NCT03782064 2023-06-22

Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma

Phase 2 Terminated

5 enrolled 8 charts

Plasma cell

Multiple Myeloma

NCT02903381 2023-06-13

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

Phase 2 Completed

8 enrolled 16 charts

Plasma cell

Smoldering Multiple Myeloma

NCT03634800 2021-08-05

RISE-M

Phase 2 Terminated

6 enrolled 11 charts

Plasma cell

Multiple Myeloma

NCT04439214 2021-04-06

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

Phase 2 Completed

47 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Turcot syndrome, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT03333746 2019-05-30

Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Terminated

1 enrolled 5 charts

Plasma cell

Multiple Myeloma

NCT03227432 2018-08-14

An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

Phase 2 Withdrawn

Plasma cell

Multiple Myeloma

Clinical Trials

CAPTUR

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

TAPUR

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

RISE-M

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma